- Pineapple Financial acquires 678,000 INJ, signaling institutional conviction and deep treasury integration within Injective’s Layer 1 framework.
- Injective expands DeFi ecosystem via Kado, Helix, and Eclipse Labs partnerships to enhance cross-chain liquidity aggregation.
Injective (INJ) is trading at $12.22, reflecting a -2.6% daily decline and a -3.5% weekly pullback, while maintaining a +38.3% increase year-over-year.
The asset currently holds a market capitalization of $1.19 billion, ranking it #112 globally, with a 24-hour trading volume of $76.9 million and a circulating supply of 97.7 million INJ. The fully diluted valuation (FDV) stands at $1.22 billion, implying minimal inflation risk, as the token supply is nearly maxed out at 100 million.
Technically, INJ is consolidating within the $12.00–$12.80 range, after failing to break out of short-term resistance near $12.85 earlier in the week. The $12.05–$12.10 zone acts as local support, and a clean break below this could open a retest of $11.70.
Conversely, a daily close above $12.90 could trigger a bullish move toward $13.50–$14.00. The RSI remains neutral near 48, showing balanced sentiment, while trading volumes suggest subdued volatility as investors await new catalysts. Despite short-term weakness, the macro trend remains bullish, supported by strong on-chain and institutional fundamentals.
Fundamentally, Injective continues to stand out as one of the most institutionally recognized Layer 1 blockchains built specifically for decentralized finance (DeFi) and derivatives markets.
The network offers native support for on-chain order books, perpetual futures, prediction markets, and cross-chain swaps, making it a high-performance alternative to Ethereum-based DEX architectures. Injective’s interoperability layer supports both EVM and non-EVM chains, including Ethereum, Solana, and Cosmos IBC, providing broad composability for liquidity aggregation and DeFi protocol integration.
A major recent development is Pineapple Financial’s $8.9 million purchase of 678,000 INJ to establish a $100 million Injective-based digital asset treasury, marking one of the most significant corporate treasury accumulations in the project’s history.
Injective’s ecosystem expansion also includes several high-profile partnerships, notably with Kado, Helix, and Eclipse Labs, strengthening its position in cross-chain payments, order routing, and modular blockchain development.
Given its strong DeFi infrastructure narrative, corporate accumulation, and stable on-chain growth, the 7-day price projection for INJ is $12.80, with potential upside toward $13.60 if bullish momentum returns.
Downside support sits at $11.95, and a loss of that level could signal a retracement toward $11.50, though current market sentiment and treasury accumulation trends favor continued mid-term strength.
